Message from the Director of the Department
In the Division of Rheumatic Diseases, we provide the diagnosis, care, and therapy of various autoimmune diseases. By the attack of immune-mediated cells and antibodies toward self-organs, the patients develop various symptoms such as fever, arthritis, muscle pain, skin rash, anemia, proteinuria, and pneumonia. Although many rheumatic diseases are often intractable, recent advances improve the prognosis. Please visit our division if you have any concerns about your diagnosis or therapy of rheumatic diseases.
Division of Rheumatic Diseases Jun Wada
Scope of Target Diseases
The Division of Rheumatic Diseases provides specialized care for various rheumatic and collagen diseases. For refractory collagen diseases that are resistant to existing therapies, we endeavor to improve clinical outcomes using state-of-the-art treatment methods such as biological products, immunosuppressive therapy, plasmapheresis, and immunoabsorption therapy. The main target disease are the following: rheumatoid arthritis, malignant rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis (scleroderma), polymyositis, dermatomyositis, mixed connective tissue disease, vasculitis (giant cell arteritis, Takayasu's arteritis, polyarteritis nodosa, microscopic polyangiitis, granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, Sjogren’s syndrome, Behcet’s disease, adult onset Still’s disease, polymyalgia rheumatica and spondylarthritis (ankylosing spondylitis, reactive arthritis and psoriatic arthritis), etc.
Features and Description of Medical Care
About 1000 patients with rheumatoid arthritis, systemic lupus erythematosus, and vasculitic syndrome, etc. are visiting us for treatment. We have a history of practice ahead of other medical institutions and plenty of experience in immunosuppressive therapy, biological products, plasmapheresis, and immunoadsorption therapy for patients with collagen disease that are severe, refractory, and accompanied with complications in addition to typical cases. Moreover, we currently provide treatment for rheumatic diseases of about 40 kinds, and also endeavor for early detection and early treatment using that experience. In addition to existing treatment, we attend various clinical trials and actively address the development of novel therapeutic strategies.